Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
phenoxodiol · 3 trials · 5 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Daily Phenoxodiol + weekly carboplatin |
| 2 | ACTIVE_COMPARATOR | Daily phenoxodiol placebo + weekly carboplatin |
| A | EXPERIMENTAL | Patients with chemotherapy naïve androgen independent disease |
| B | EXPERIMENTAL | Patients with rising PSA after radical prostatectomy or radiotherapy that are androgen dependent |
| Arm A | EXPERIMENTAL | Phenoxodiol IV 3 mg/kg combined with cisplatin 40 mg/m2 on Day 2 6 week cycles |
| Arm B | EXPERIMENTAL | Phenoxodiol IV 3 mg/kg combined with paclitaxel 80 mg/m2 on Day 2 6 week cycles |
| Name | Type | Description |
|---|---|---|
| phenoxodiol | DRUG | 400mg phenoxodiol three times daily in 28 day cycles. |
| carboplatin | DRUG | AUC=2 weekly in 28 day cycles |
| placebo | DRUG | every 8 hours daily in 28 day cycles |
| cisplatin | DRUG | IV 40 mg/m2 on Day 2 Number of Cycles: until progression or unacceptable toxicity or other withdrawal criteria are met. |
| paclitaxel | DRUG | IV 80 mg/m2 on Day 2 Number of Cycles: until progression or unacceptable toxicity or other withdrawal criteria are met. |
Inclusion Criteria: * Histologically-confirmed ovarian, fallopian, or primary peritoneal carcinoma of epithelial origin * Recurrent or persistent advanced disease * Have measurable disease * Undergone at least two courses of therapy with a platinum drug (cisplatin or carboplatin) and have responded...
Phenoxodiol is an investigational small molecule being studied for the treatment of fallopian tube cancer and prostate cancer. It has also been evaluated in clinical trials for ovarian cancer and primary peritoneal cavity cancer. The drug is currently in Phase 2 clinical development for these oncology indications.
Phenoxodiol is a small molecule that has been studied in combination with chemotherapy agents such as cisplatin and paclitaxel. Its mechanism of action involves sensitizing cancer cells to the effects of these chemotherapeutic drugs, potentially enhancing their antitumor activity in ovarian, fallopian tube, and prostate cancers.
Phenoxodiol is being developed by Lite Strategy, Inc., a company listed on the stock exchange under the ticker symbol LITS. The company is conducting clinical research to evaluate the drug's safety and efficacy in treating various gynecologic and prostate malignancies.
Phenoxodiol is currently in Phase 2 clinical development. It has completed two clinical trials, including a Phase 1 study and a Phase 3 study, with a total enrollment of 207 patients across all trials. The drug remains investigational and has not been approved by regulatory authorities.
Phenoxodiol has completed three clinical trials. NCT00091377 was a Phase 1 study combining phenoxodiol with cisplatin or paclitaxel in patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer. NCT00382811 was a Phase 3 study of weekly carboplatin with or without phenoxodiol in platinum-resistant ovarian cancer. NCT00557037 was a Phase 2 trial in prostate cancer.
Phenoxodiol is not the same as OVATURE. OVATURE is the name of a clinical trial, specifically the OVArian TUmor REsponse study, which evaluated weekly carboplatin with or without phenoxodiol in patients with platinum-resistant, recurrent epithelial ovarian cancer. Phenoxodiol is the investigational drug being tested in that trial.